These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

939 related items for PubMed ID: 15753888

  • 21. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
    Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, Cooper PJ.
    Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
    [Abstract] [Full Text] [Related]

  • 22. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
    D'Amato G, Liccardi G, Noschese P, Salzillo A, D'Amato M, Cazzola M.
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO, Strohner P, Zimmer KP, Lindemann H.
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R.
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [Abstract] [Full Text] [Related]

  • 28. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment.
    van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF.
    Allergy; 2009 Jan; 64(1):72-80. PubMed ID: 19076931
    [Abstract] [Full Text] [Related]

  • 29. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
    Hamilton RG, Marcotte GV, Saini SS.
    J Immunol Methods; 2005 Aug; 303(1-2):81-91. PubMed ID: 16045925
    [Abstract] [Full Text] [Related]

  • 32. Anti-IgE treatment in allergic rhinitis.
    Bayar Muluk N, Bafaqeeh SA, Cingi C.
    Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y.
    Curr Med Res Opin; 2003 Dec; 19(6):491-8. PubMed ID: 14594521
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Seasonal variations of serum-IgE and potential impact on dose-calculation of omalizumab (rhuMab-E25, anti-IgE)].
    Beeh KM, Beier J, Buhl R.
    Pneumologie; 2004 Aug; 58(8):546-51. PubMed ID: 15293167
    [Abstract] [Full Text] [Related]

  • 36. Omalizumab in asthma: approval and postapproval experience.
    Chiang DT, Clark J, Casale TB.
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080
    [Abstract] [Full Text] [Related]

  • 37. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV.
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [Abstract] [Full Text] [Related]

  • 38. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M.
    J Immunol Res; 2016 Jun; 2016():8163803. PubMed ID: 28097159
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 40. Omalizumab in allergic diseases, a recent review.
    Vichyanond P.
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.